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Introduction: In addition to emphysema alpha-1-antitrypsin deficiency (AATD) has been shown
to be associated with several inflammatory conditions, including bronchiectasis, vasculitis, (in
particular Wegener’s granulomatosis), and panniculitis, suggesting neutrophil proteinases also
play a role in their pathophysiology. However, it remains unknown whether other inflammatory
diseases are also more prevalent in AATD than the general population. The current study de-
scribes the prevalence of other co-morbidities in AATD with particular emphasis on inflamma-
tory bowel disease.
Methods and results: The case notes of 651 PiZZ or PiZnull patients attending the UK national
centre for AATD between 1996 and 2011 were reviewed. The prevalence of inflammatory bowel
disease (1.5%) was higher than that predicted in the UK (0.4%). Ten patients had a confirmed
diagnosis of ulcerative colitis, and 1 had Crohn’s disease. In 2 cases there was a family history
of inflammatory bowel disease and all but 1 patient were ex or never smokers. There was also a
higher prevalence of hypothyroidism in this patient group than expected for the UK population
e 26 cases (7.2% of females and 1.3% of males).
Conclusions: The current study of the UK cohort of patients with AATD confirmed a higher prev-
alence of ulcerative colitis than would be expected in the general population, providing
further evidence of a potential link between these 2 conditions. In addition, the data sug-
gested a potential link between hypothyroidism and AATD.
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Table 1 Demographic data for the 10 patients with AATD
and UC.
Male (%) 4 (40)
Age at UC diagnosis 37.4 (5.1)
Age at AATD diagnosis 35.1 (6.4)
AAT level (mm) 4.1 (1.2)
FEV1 (L) 2.7 (1.8)
FEV1% predicted 98.0 (45.8e117.8)
FVC (L) 4.9 (3.94e6.0)
FVC% predicted 123.2 (22.8)
FEV1/FVC ratio 56.3 (23.2)
TLC (L) 6.8 (1.7)
TLC% predicted 120.9 (8.2)
KCO mmol/min/kPa/L 1.2 (0.3)
KCO% predicted 73.3 (15.8)
RV/TLC% 41.9 (1.8)
Smokers (%) 7 (70)
Pack year history 9.5 (3.7)
CT emphysema alone (%) 3 (30)
CT bronchiectasis (%) 1 (10)
CT emphysema and bronchiectasis (%) 3 (30)
SGRQ impact 28.7 (9.3e42.5)
SQRG activity 50.4 (18.1e80.9)
SGRQ symptoms 62.8 (41.8e61.2)
SGRQ total 42.7 (19.5e58.6)
Data are shown as mean values with SD in parentheses or me-
dian with IQR in parentheses, apart from the proportion of
males, smokers and those with CT abnormalities shown as
number and % in parentheses.
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Co-morbidities are becoming increasingly recognised in
patients with usual COPD. Cardiovascular disease, the
metabolic syndrome and osteoporosis all occur more
frequently than expected and may have a common in-
flammatory pathway [1].
Alpha-1-antitrypsin deficiency (AATD) of the PiZZ geno-
type has a prevalence of 1 in 2500 in the UK and is the only
widely recognised genetic factor that increases suscepti-
bility to develop COPD [2]. This severe form of the defi-
ciency results in a critically low level of AAT that reduces
the ability to protect tissues from the bystander damage
caused by proteolytic enzymes from the neutrophil,
including neutrophil elastase and proteinase 3 [3,4]. This
excessive damage may be central to the processes seen in
panniculitis and arteritis which are both neutrophilic con-
ditions [5] and more frequent in subjects with AATD [6]
suggesting cause and effect.
Little is known about other co-morbidities in AATD that
have a neutrophilic pathophysiology although there has
been a suggested link with inflammatory bowel disease [7].
The UK registry for AATD has comprehensive physiolog-
ical and radiological data but also documents co-
morbidities and their temporal relationship to the diag-
nosis of AATD. The current project was undertaken to
determine the frequency of other co-morbidities with an
inflammatory basis in patients with AATD.
Methods
The ADAPT programme is the UK national centre for pa-
tients with AATD, established in 1996, which documents the
patients in detail, including past and present medical
history.
A retrospective review was undertaken of the first 651
consecutive patients joining the registry with the PiZZ or
PiZnull phenotypes from 1996 to September 2011. AATD
phenotype and genotype was confirmed in all patients
based on dried blood spots by a single laboratory (Hered-
ilab, Salt Lake City, Utah).
Data on all co-morbidities was extracted from the case
notes for each of the patients. It was noted that 2 co-
morbidities appeared to be more prevalent than antici-
pated; namely inflammatory bowel disease and hypothy-
roidism, therefore they were selected for further analysis
for the current report. In those in whom a diagnosis of IBD
was recorded, confirmation was sought from the individ-
ual patients’ primary care physician, together with the
date of diagnosis, where the diagnosis was made, and
whether any family history of inflammatory bowel disease
was known.
In the patients in whom a diagnosis of hypothyroidism
had been recorded, confirmation of the diagnosis was also
sought from the patients’ primary care physician, including
date of diagnosis and the presence or absence of thyroid
autoantibodies. Where autoantibodies were not docu-
mented thyroid peroxidase (TPO) autoantibodies were
measured in the patients’ stored plasma using a fluores-
cence enzyme immunoassay (FEIA e a sandwich immuno-
assay) and expressed as a value in arbitrary units (au).Other demographic data for patients with IBD or thyroid
disease was extracted directly from the registry database.
Data analysis was undertaken using Microsoft Excel 2007
and SPSS version 17 (Chicago Ill). Ethical approval for the
study was approved by the South Birmingham Ethics Com-




There were 11 patients from this UK cohort who had a diag-
nosis of IBDdocumented in the casenotes (2 ofwhomalsohad
a family history of IBD). The diagnosis was of UC in 10 pa-
tients, and Crohn’s disease in the remaining patient. In each
case, the patients’ primary care physician confirmed both
the diagnosis and the date of diagnosis. There was one
further patient who had a diagnosis of IBDmade in secondary
care, and had undergone a surgical resection of the large
bowel, but in whom the definitive diagnosis of UC or Crohn’s
was not made. Data from this individual was therefore
excluded from the UC series, in the current study. The de-
mographic data for the 10 patients with confirmed UC and
AATD are presented in Table 1.
There were 4 male and 6 female patients, which is
consistent with the even sex distribution of UC in the general
population. The overall prevalence rate of UC in this patient
cohort was 1.5% (10 of 651 patients), which is equivalent to
Table 2 Demographic data for the 26 patients with A1ATD
and hypothyroidism.
Female (%) 21 (81)
Male (%) 5 (19)
Age at hypothyroidism diagnosis 46.6 (1.9)
Age at A1ATD diagnosis 51.2 (2.4)
FEV1 (L) 2.0 (0.8)
FEV1% predicted 73.3 (26.6)
FVC (L) 3.7 (0.9)
FVC% predicted 114.3 (21.9)
FEV1/FVC ratio 53.3 (16.5)
TLC (L) 5.7 (4.9e7.3)
TLC% predicted 114.2 (15.6)
KCO mmol/min/kPa/L 1.2 (0.4)
KCO% predicted 74.5 (24.6)
SGRQ impact 53.7 (19.7)
SGRQ activity 60.3 (27.2)
SGRQ symptoms 30.0 (8.8)
SGRQ total 43.2 (19.5)
Female and male are the number of patients included in the
analysis with % in parentheses. Age at hypothyroid/AATD diag-
nosis is the mean in years with SD in parentheses. Lung function
is given as the mean or median absolute values or as % predicted
with SD or IQR in parentheses.
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400 per 100,000 in the general UK population [8].
The 10 patients were subdivided into those in whom the
diagnosis of UC was made before or after the diagnosis of
AATD in order to reduce any potential selection bias (due to
a more comprehensive health assessment because AATD
had been identified). In 6, a diagnosis of UC (0.9% preva-
lence) preceded that of AATD, which still equates to 921
cases per 100,000, more than 2 times higher than expected
in the adult UK population.
The patients in general had airflow obstruction (mean
FEV1/FVC ratio of 56.3%), air trapping with a raised RV/TLC
ratio (mean 41.9%) or hyperinflation with a raised TLC
(meanZ 120.9% predicted) and reduced gas transfer (mean
KCO Z 73.3% predicted). Eight of the patients were index
cases, 6 having presented with respiratory symptoms
before the diagnosis of AATD was made. However, 2 of the
patients were non-index having been identified by family
screening and had normal lung function.
The CT findings for the 8 index patients with UC are
shown in Table 1. All of the scans were performed at the
same centre, and reported by a single thoracic radiologist.
One patient had a normal scan, and of the remaining 7, 6
had demonstrable emphysema and 4 had bronchiectasis (3
with emphysema) e see Table 1.
Seven patients had a smoking history, (1 patient was a
current smoker) and the mean pack year smoking history
was 9.5 pack years (SD 8.7). The 6 former smokers had
stopped smoking before the diagnosis of UC had been
made, consistent with presentation of UC in the general
population [9].Thyroid disease
There were 26 patients within the cohort with a confirmed
diagnosis of hypothyroidism, all receiving thyroxine (4% of
the cohort). A further 3 patients had hypothyroidism (1
following treatment with amiodarone and 2 following thy-
roid surgery for hyperthyroidism) and were excluded from
further analysis. The demographic data for the 26 patients
is presented in Table 2.
Twenty-one were female, consistent with the sex dis-
tribution of hypothyroidism in the general population,
where the anticipated prevalence is up to 1.2% of women
and 0.4% of men [10].
Amongst the total cohort of AATD patients included in
this analysis, there were 272 females (42%) and 379 males
(58%). Based on this number, the prevalence of hypothy-
roidism amongst females was 7.7% and 1.3% amongst males,
both being higher than predicted in the UK population.
Again, in order to reduce any selection bias, the group was
divided into patients diagnosed with hypothyroidism
before, and those in whom the diagnosis was made after
the diagnosis of AATD. Fifteen patients (14 female 1 male)
had a diagnosis of hypothyroidism made before AATD was
diagnosed giving adjusted prevalence rates of 5.2% for fe-
male and 0.5% of male patients, again being higher than
expected though only for female patients.
Thyroid autoantibodies were measured in 21 of the 26 pa-
tients and were positive in 8 patients (38% of those in whom
they were measured e with a range of 136 au to 2312 au).The lung function parameters for this group of patients
again demonstrated airflow obstruction with a reduced
FEV1/FVC ratio of 53.3%, an average TLC of 114.3% pre-
dicted consistent with hyperinflation. The KCO% was also
reduced on average to 74.5% predicted in keeping with
emphysema secondary to alpha-1-antitrypsin deficiency.
Other recognised disease associations
Of the other previously described disease associations of
AATD, in the UK cohort of patients, 26 (4.0%) had a primary
diagnosis of liver cirrhosis, with 8 having undergone liver
transplantation, and a further 12 patients had abnormal
basic liver function tests (including bilirubin, transaminases
and alkaline phosphatase) and were under regular liver
follow up. Five patients (0.8%) had a diagnosis of Wegener’s
granulomatosis and 6 (0.9%) had panniculitis.
Discussion
This unique dataset, from the only extensive registry of
AATD patients in the UK, provides further evidence to
support a possible link between AATD and other inflam-
matory and autoimmune conditions. The data consolidates
the association with UC as previously suggested [7,11] but
uniquely identifies an association with thyroid disease,
which has not been reported previously.
UC
A potential link between AATD and IBD was suggested from
the Swedish cohort where it was reported that 1.2% of
patients with the PiZ phenotype of AATD also had UC [11].
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on a Swedish registry of UC for AATD; 8.4% were found to be
MZ heterozygotes, which is higher than the expected
prevalence of 4.2% in the general Swedish population [11].
Since MZ subjects also have reduced levels of AAT the data
suggested that severity of UC related in part to a reduced
ability to inhibit serine proteinase related bowel damage
[11].
The Mayo clinic published a series of 10 patients iden-
tified over a 20-year period who had AATD and IBD listed as
concurrent diagnoses [7]. Of these, 7 had UC, 3 of whom
were heterozygotes for AATD (MZ phenotype), and 3 had
CD. They reported a higher then expected number of these
patients required surgical intervention following a failure of
medical therapy, again suggestive of a worse clinical course
amongst AATD deficient individuals [7].
The observed prevalence of UC reported here did not
include or study MZ heterozygotes (because of the nature
of the database) but was still 4 times greater than expected
for a UK population in subjects with severe (PiZZ or PiZnull)
AATD. The reasons for the association are not well under-
stood. It has previously been postulated that a link between
IBD and respiratory diseases in general may, in part, be
explained by the common embryonic origins of the lung and
bowel (both originate from the endoderm) [12] and due to
similarities in the structure of the lumen of the airway and
bowel (both contain goblet cells and submucosal glands).
Both the lung and bowel have an important role in the
immune system and host defence, and contain lymphoid
tissue [12]. The interactions between the immune system
and these 2 organs is complex; case reports have suggested
that a proportion of patients with IBD who underwent sur-
gical interventions including colectomy, developed respi-
ratory symptoms postoperatively, suggestive of
bronchiectasis [12]. In the series reported by Kelly et al.,
which included 5 patients with UC and 5 with Crohn’s, the
presentation of respiratory symptoms was variable, and the
timescale of onset ranged from 2 weeks to 30 years [12].
The prevalence of respiratory disease in the cohort
presented here was high as would be expected in AATD
(especially smokers). However, it should be noted that most
(5 of the 7 smokers) had stopped smoking before UC was
diagnosed consistent with the natural history of UC in the
general population [9].
The underlying pathophysiology of colitis complex;
however there is data to support the role of the neutrophil
in both host defence of the GI tract under healthy condi-
tions, although in the presence of pathological conditions,
such as in inflammatory bowel disease, their response may
result in mucosal injury [13]. In inflammatory disease it
might be predicted that UC in patients with reduced AAT
levels would be less protected from damage by neutrophil
serine proteinase especially during acute episodes, than
those with normal levels of AAT. Indeed, this was inferred
by the paper by Yang et al. in established UC in subjects
with partial deficiency due to the heterozygote state who
had a more severe clinical course [7].
The current study had no control group with which to
compare the severity of UC in AATD. However, the preva-
lence was high suggesting the low AAT level may in itself be
a risk factor. Minor degrees of bowel inflammation may lead
to excessive neutrophil mediated damage in AATD subjects,precipitating the symptoms, signs and pathology of UC.
Whether augmentation therapy to normalise the AAT
plasma concentration would decrease the severity or
prevalence of UC in subjects with AATD is worthy of
exploration in other cohorts where such therapy is
available.
In IBD, several genes have been implicated in the path-
ogenesis of UC, including those on chromosomes 1, 3, 5,
6,7,12, 14 and 19 [14]. None of these loci have been found
to be consistently at fault, and thus there has been no
suggestion of a common underlying genetic defect to link
AATD with UC [14]. Therefore, the association described
here is more likely to have arisen as a result of excessive
damage by neutrophilic inflammation as a result of AATD
itself. The increased incidence may therefore reflect the
reduction in protection from initial damage in AATD thereby
amplifying the pathophysiology.
The combination of inflammatory disease in 2 organs
may possibly reflect an ‘overspill’ phenomenon [15] which
could provide a mechanism of both lung disease and IBD as
well as for other co-morbidities in usual COPD. However,
further studies in well described and large cohorts of both
diseases will be needed to elucidate the precipitating
mechanism(s) and whether the systemic inflammation in
these with co-morbidities exceeds or differs from that
reflecting the severity of the lung disease alone.Hypothyroidism
Work describing a potential link between usual COPD and
thyroid disease has been less well described than that for
inflammatory bowel disease, and with conflicting results.
Okutan et al. [16] found an association between PaCO2
and free T3 in 32 patients with stable COPD. Conversely,
Gow and colleagues found no association between blood
gas measurements and thyroid function tests [17]. A link
between treated hypothyroidism, airway inflammation
and airflow obstruction has been suggested in non-
smoking individuals [18,19] however no previous data ex-
ists on the prevalence of thyroid disease in patients with
AATD.
Our study shows an increased prevalence of hypothy-
roidism compared to the general UK population (6 fold for
females and 3 fold for males). Again, to reduce any diag-
nostic bias, patients were divided into those diagnosed with
thyroid disease prior to a diagnosis of AATD and there was
still an increased prevalence amongst female patients at
5.2%, although the prevalence amongst male patients was
no longer different to that expected in the general popu-
lation. The overall observation is consistent with a role of
autoimmunity as autoimmune conditions in general are
more common amongst females.
Thirty eight % of our patients had positive thyroid au-
toantibodies. In a previous study in non-smoking COPD 96%
of the hypothyroid patients had positive antibody results,
from which they concluded that autoimmunity was likely to
be the basis [18]. In the AATD group of patients, both male
and female patients were included in the analysis, whereas
all of the 26 patients included in the Birring series were
female [18]. As autoimmune diseases in general are more
common in females, this may account for the difference in
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theless, when we analysed the females alone, the preva-
lence of autoantibodies remained less than that observed
by Birring and colleagues [19] suggesting an alternative
mechanism in AATD.
The reasons for an association between respiratory dis-
ease and hypothyroidism are not well understood, although
autoimmunity has been suggested in the pathogenesis of
COPD [20]. In AATD lung disease, autoimmunity is not
considered to play a significant role [21] and thus the
pathophysiological processes may differ from usual COPD.
Birring et al. discovered that sputum levels of IL8 and
neutrophil counts were higher in patients with hypothy-
roidism compared to healthy control subjects [18], again
suggesting an inflammatory link, and certainly lung
inflammation is even more likely to be high in patients with
AATD [22]. Therefore the potential association between
patients with AATD and hypothyroidism may be more
complex involving both autoimmunity and neutrophilic in-
flammatory processes.Other disease associations
The number of patients with established liver disease
amongst our cohort was low (26 or 4%) and less than that
described recently by Dawwas and colleagues where 63%
had a history suggestive of liver disease [23]. This disparity
likely represents selection bias of the patients recruited to
each centre, where referral to ADAPT is primarily for res-
piratory reasons rather than AATD alone. Only 3 of the
patients referred to the centre with respiratory symptoms
have developed progressive liver failure to date.
Panniculitis prevalence in our cohort was higher than the
previously suggested value of 1 in 1000 patients with AATD
[24]. There were 6 patients in the ADAPT database with
panniculitis recorded as co-morbidity, equivalent to 9 pa-
tients per 1000. Of these 6 individuals, 4 had severe pan-
niculitis with previous ulceration of the lesions, requiring
augmentation therapy with pooled human AAT. Although
this is a licensed indication for intravenous AAT in the UK,
the patients with severe panniculitis had been referred
specifically to obtain advice on this treatment strategy and
thus the higher incidence reported here than in other series
[24] likely reflects this referral bias.
An overall potential limitation of our study is that the
results reflect a diagnostic, selection and referral bias.
Recognition of one illness (especially AATD) may lead to
more awareness and exploration of other health prob-
lems. For these reasons, we analysed data from in-
dividuals who were diagnosed with either UC or thyroid
disease before the diagnosis of AATD was made. Even
following this adjustment, the rates of UC and thyroid
disease remained greater than expected in the general
population of the UK, providing firmer evidence to link
both IBD and thyroid disease with respiratory disease
related to AATD. Patients with the AATD PiZZ genotypes
are deemed most at risk of developing lung disease, and
hence are followed up at this National Centre, together
with those with other rare genotypes. Patients with the
PiMZ genotype account for 2e3% of the population [23],
and such individuals have 60% of the normal level ofcirculating AAT, and therefore are not deemed at risk of
developing lung disease. Heterozygotes are not routinely
followed up at our centre, and thus we were unable to
confirm whether these co-morbidities are also increased
in the MZ patients as suggested previously [7].
Conclusion
Our observations have confirmed an association between
AATD and UC, and identified a link with hypothyroidism. UC
would be an important diagnosis to exclude in patients with
AATD who present with gastrointestinal symptoms, and
conversely, patients with IBD should be tested routinely for
AATD, especially if respiratory symptoms are also present.
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